Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) will report financial results for the third quarter ended December 31, 2025 and provide a business update on Friday, February 6, 2026 at 8:00 a.m. ET. Investors can access a conference call (phone registration required) hosted with Roivant (Nasdaq: ROIV) and a live webcast. Presentation materials and a webcast archive will be available in the Investors "News & Events" section of Immunovant's website after the call.

Key Figures

Earnings call time: 8:00 a.m. ET Quarter end date: December 31, 2025

2 metrics

Earnings call time 8:00 a.m. ET Scheduled business update on February 6, 2026

Quarter end date December 31, 2025 Third quarter reporting period referenced in announcement

Market Reality Check

Price: $26.60 Vol: Volume 1,130,268 is at 0....

normal vol

$26.60 Last Close

Volume Volume 1,130,268 is at 0.74x the 20-day average of 1,518,032 shares. normal

Technical Price $26.01 is trading above the 200-day MA of $18.52 and 6.44% below the 52-week high of $27.80.

Peers on Argus

IMVT gained 0.61% while key biotech peers like SRRK (-6.13%), VKTX (-4.70%), MLY...

IMVT gained 0.61% while key biotech peers like SRRK (-6.13%), VKTX (-4.70%), MLYS (-3.22%), and SLNO (-2.75%) declined, indicating stock-specific strength rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 11 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 11	Equity financing	Negative	+5.3%	Priced $550M common stock offering at $21.00 per share.
Nov 10	Earnings and updates	Neutral	+0.1%	Reported Q2 financials and multi-indication IMVT-1402 clinical updates.
Oct 27	Earnings date notice	Neutral	+2.6%	Announced timing and access details for upcoming Q2 results call.
Sep 03	Clinical data update	Positive	+10.8%	Reported six‑month remission and treatment-free data in Graves’ disease.
Aug 11	Earnings and pipeline	Neutral	-4.5%	Quarterly results with higher R&D and progress on registrational studies.

Pattern Detected

IMVT has shown strong positive reactions to clinical data, while financing and routine scheduling or earnings updates have produced mixed and sometimes contrary price moves.

Recent Company History

Over the last six months, Immunovant has combined financing, clinical progress, and regular earnings communication. A September 2025 Graves’ disease remission update drove a 10.82% gain, highlighting the market’s focus on clinical durability data. An August and November 2025 earnings cycle emphasized cash runway into a potential 2027 readout, with modest to negative price reactions. A December 2025 $550 million equity financing surprisingly coincided with a 5.31% rise. Prior quarter’s earnings-date scheduling in October saw a 2.57% move, providing a reference for today’s upcoming earnings-timing announcement.

Market Pulse Summary

This announcement sets the timetable for Immunovant’s third‑quarter results for the period ended Dec...

Analysis

This announcement sets the timetable for Immunovant’s third‑quarter results for the period ended December 31, 2025, with a business update scheduled for 8:00 a.m. ET on February 6, 2026. Recent history shows that detailed clinical readouts and financing terms have driven the largest moves, while prior earnings and scheduling updates produced smaller, mixed reactions. Investors reviewing this event may focus on how upcoming commentary relates to cash runway, ongoing registrational trials, and previously highlighted Graves’ disease milestones.

AI-generated analysis. Not financial advice.

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com

Media
Stephanie Lee
stephanie.lee@roivant.com

FAQ

When will Immunovant (IMVT) report Q3 2026 financial results?

Immunovant will report results for the third quarter ended December 31, 2025 on February 6, 2026 at 8:00 a.m. ET.

How can investors join the Immunovant (IMVT) earnings call on February 6, 2026?

Investors may register online to access the conference call by phone and can join the live webcast via the company's Investors "News & Events" page.

Will Immunovant (IMVT) provide slides or a webcast of the February 6, 2026 update?

Yes. Presentation materials and a webcast will be available during the event and an archived webcast will be posted on Immunovant's investor website after the call.

Is Roivant (ROIV) involved in the Immunovant (IMVT) February 6, 2026 call?

The notice indicates access to the Roivant (Nasdaq: ROIV) conference call by phone is available via online registration.

Where can I find the archived webcast and presentation for Immunovant (IMVT)?

The archived webcast and presentation will be posted under Investors > News & Events on Immunovant's website after the conference call.